Positive interim results from the Phase III DESTINY-Breast09 trial revealed that ENHERTU® (fam-trastuzumab deruxtecan-nxki), ...

Phase 1b Beamion LUNG-1 trial data at AACR 2025 showed zongertinib yielded responses in pretreated HER2-mutant NSCLC, ...

Runimotamab plus trastuzumab resulted in positive clinical activity and tolerability over runimotamab alone in patients with ...

In a Phase I study presented at AACR's annual meeting, 71 percent of patients who hadn't received a prior anti-HER2 ADC responded to the drug.

A combination of pertuzimab and Enhertu can slow disease progression and improve survival in people with HER2-positive ...

Roche has claimed a breakthrough designation from the FDA for a cancer test that combines an antibody assay with ...

The investigational oral tyrosine kinase inhibitor (TKI) zongertinib showed promise in patients with previously treated HER2 ...

Narrow-moat Daiichi Sankyo is a Japanese drugmaker with a global footprint and cutting-edge development platform for antibody drug conjugates. As an established pharmaceutical company with a long ...

Zongertinib, an oral therapy shown to have strong responses in patients previously treated for HER2 -mutated non–small cell ...

Boehringer Ingelheim unveiled new data from its top oncology prospect zongertinib, further backing the drug’s prowess in ...

The DXd ADC portfolio currently consists of ENHERTU, a HER2 directed ADC, and DATROWAY, a TROP2 directed ADC, which are being jointly developed and commercialized globally with AstraZeneca.

Donna McMenamin is one of thousands of breast cancer patients in the UK caught up in a disagreement over costs between the ...